Brought to you by 
ObsEva Licenses Exclusive Rights to Kissei's Endometriosis Candidate; Agreement Amended; Agreement Terminated
28 Jul 2022
Executive Summary
Kissei Pharmaceutical Co. Ltd. granted ObsEva SA exclusive worldwide rights (excluding Asia) to its Phase II endometriosis candidate KLH2109, which ObsEva will develop as OBE2109 for that and other gynecologic conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ObsEva Licenses Exclusive Rights to Kissei's Endometriosis Candidate; Agreement Amended; Agreement Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice